Company News:
Molecular Health To Attend Key Events and Scientific Conferences In The Fourth Quarter 2018

Heidelberg, Germany and Boston, USA - October 1, 2018 – Molecular Health (MH), a leading biomedical company that is transforming molecular data into clinically actionable information for efficient and safer cancer treatment options based on its proprietary Dataome® technology platform, announced that the company is going to attend several industry and scientific conferences in the fourth quarter 2018.

Bill and Melinda Gates Foundation Grand Challenges Meeting. October 15-18, 2018 - Berlin, Germany. Attendance: 1 poster and 1 workshop.

ESMO2018 – European Society for medical oncology congress. October 19-23, 2018 - Munich, Germany. Attendance: Molecular Health booth.

Executive Decision-Making Conference - Portfolio Management. October 23-24, 2018 - Hyatt at the Bellevue, Philadelphia. Attendance: 1 oral presentation.
- Predicting clinical trial success with Artificial Intelligence, 23 October at 9:30 am

AMP 2018 - AMP Conference. October 31 - November 3, 2018 - San Antonio, TX, USA. Attendance: MH Booth 803 and Corporate Workshop.

Personalized Medicine Coalition. November 13-15, 2018 – Harvard, USA. Attendance: Molecular Health Table Presentation.

15. AIO-Herbstkongress 2018 - Update on Medical Oncology. November 15-17, 2018 – Berlin, Germany. Attendance: Molecular Health booth.

Biodata World Congress. November 28-29, 2018 – Basel Congress Center, Basel. Attendance: 1 oral presentation and 1 booth
- Predicting clinical trial success with Artificial Intelligence, November 29, 2018.

About Molecular Health

Molecular Health (MH) is a global computational biomedicine company focused on the capture, curation, integration, and analysis of large data sets in the field of biomedicine and medical products and combining them with novel artificial intelligence and machine learning (AI/ML) technologies to enable precision medicine. Over more than a decade, the company has developed Dataome®, a unique, high-quality curated system that combines clinico-molecular data, drug data and analytical processes. Dataome®, in combination with novel AI/ML technologies, allows for new approaches for prognostic and predictive in silico science that can guide some of the most promising yet most challenging promises of precision medicine. Based on its unique technology MH offers products and solutions for physicians, providers, pharma and laboratories. The company is headquartered in

Heidelberg, Germany, the center of cancer research in Europe. The U.S. headquarter is located in Boston, MA.

For more information, visit www.molecularhealth.com

Carla Mertens
Molecular Health GmbH
Carla.mertens@molecularhealth.com